Product Information

Casopitant is a piperidine compound.

CAS No.	414910-27-3
Product Name	Casopitant

Biological Targets

TACR1

Associated Conditions

Nausea and vomiting·Chemotherapy-induced nausea and vomiting·Nausea·Vomiting·Sleep Disorder·

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

The Lancet. Oncology • Vol. 10, Issue 6 • 2009

PMID: 19428297 DOI: 10.1016/S1470-2045(09)70109-3

Disposition and metabolism of radiolabeled casopitant in humans.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 37, Issue 8 • 2009

PMID: 19420128 DOI: 10.1124/dmd.109.026781

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • Vol. 17, Issue 9 • 2009

PMID: 19205754 PMC: PMC2726911 DOI: 10.1007/s00520-008-0572-4

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • Vol. 17, Issue 9 • 2009

PMID: 19205755 PMC: PMC2726912 DOI: 10.1007/s00520-008-0571-5

Casopitant

CAS No.	414910-27-3
MDL No.	N/A
MF	C₃₀H₃₅F₇N₄O₂
MW	616.60
InChI Key	XGGTZCKQRWXCHW-WMTVXVAQSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Casopitant is a piperidine compound.

CAS No.	414910-27-3
Product Name	Casopitant

Biological Targets

TACR1

Associated Conditions

Nausea and vomiting·Chemotherapy-induced nausea and vomiting·Nausea·Vomiting·Sleep Disorder·

* The information provided here is compiled from public sources and is for reference only.

Casopitant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Casopitant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Casopitant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

Disposition and metabolism of radiolabeled casopitant in humans.

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.

Similar Products

Casopitant Mesylate

Orvepitant

Casopitant

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

Disposition and metabolism of radiolabeled casopitant in humans.

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.

Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.

Similar Products

Casopitant Mesylate

Orvepitant

Documentation